-
hiPSC Intestinal Organoids for Pharmacokinetics
2026-09-17
Saito and colleagues established a streamlined direct 3D culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The resulting organoids can be propagated, cryopreserved, and converted into epithelial monolayers containing functionally relevant enterocytes, creating a human-relevant platform for studying intestinal drug absorption and metabolism.
-
MK 0893 Glucagon Receptor Antagonist Workflows
2026-09-16
MK 0893 combines nanomolar GCGR potency with a structurally defined allosteric mechanism, making it useful for cAMP assays, receptor selectivity studies, and translational metabolic models. This guide converts those properties into practical cell-based workflows, formulation controls, and troubleshooting decisions for type 2 diabetes research.
-
circ_0042103/TAF15/NER Axis in Pulpitis
2026-09-15
This study defines a circ_0042103/TAF15/NER regulatory axis linking circular RNA activity with DNA damage and inflammation in dental pulp stem cells. Its combined transcriptomic, cellular, and molecular-interaction approach suggests that circ_0042103 may intensify pulpitis by reducing ERCC1 and PCNA-associated repair activity.
-
APEX2 Promotes TERT Expression in Human Stem Cells
2026-09-15
A 2024 bioRxiv preprint identifies APEX2 as a DNA repair enzyme required for efficient TERT expression and telomerase activity in human embryonic stem cells and a melanoma cell line. Its combined knockdown, transcriptomic, and chromatin-binding analyses suggest that repair of damage-prone repetitive DNA, rather than direct promoter occupancy, may connect APEX2 to TERT regulation.
-
Nullscript: HDAC Inhibitor Workflow Guide
2026-09-14
Nullscript is a histone deacetylase inhibitor designed for mechanistic studies where HDAC blockade must be separated from transcriptional facilitation. This guide outlines formulation, cell-based, cardiac I/R, and exploratory necroptosis workflows while clearly distinguishing established evidence from testable applications.
-
Vernakalant Hydrochloride: AF Assay Workflows
2026-09-14
Build exposure-aware ion-channel and cardioversion assays around Vernakalant Hydrochloride, the atrial-selective research tool also known as RSD1235. This guide connects multi-channel electrophysiology with clinically relevant timing, concentration selection, and troubleshooting for rapid conversion of atrial fibrillation research.
-
Magneto-Piezoelectric Scaffolds for Infectious Bone Repair
2026-09-13
This ACS Nano study introduces a multifunctional scaffold that combines magnetic biofilm disruption with ultrasound-regulated immune and metabolic activation for infectious bone-defect repair. Its central finding is that targeted reprogramming of Icam1+ macrophages through oxidative phosphorylation, involving JAK2–STAT3 and MAPK–JNK signaling, can connect infection control with bone regeneration.
-
Mouse Tissue Lysis Kit K1038: Protocol & QC
2026-09-12
The Mouse Tissue Lysis Kit (K1038) prepares mouse tissue lysates for direct PCR-based genotyping without a separate DNA extraction or purification step. It is intended for molecular biology research, DNA analysis, and assay development, not for diagnostic, clinical, or medical use.
-
HSP90 Modulates RNA Foci in DM1
2026-09-12
Johnson and colleagues used an unbiased small-molecule RNA-FISH screen to identify HSP90 as a regulator of pathogenic DMPK RNA and CUG-repeat RNA foci in myotonic dystrophy type 1. The study connects HSP90 activity to p-STAT3 signaling in undifferentiated myoblasts, while showing that differentiation reverses the DMPK response to HSP90 inhibition.
-
In Vitro Drug Responses: Growth Versus Cell Death
2026-09-11
Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that drug-induced growth inhibition and cell killing are related but non-equivalent biological outcomes. The work supports time-resolved, orthogonal response measurements so that in vitro cancer drug studies do not mistake proliferative arrest for cytotoxicity.
-
IEM-1925 for Soman-Induced Status Epilepticus
2026-09-10
A 2026 NeuroToxicology study shows that IEM-1925 can suppress soman-induced status epilepticus while reducing hippocampal injury and behavioral deficits in rats. Its value lies in integrating EEG, histopathology, survival, and behavioral endpoints to evaluate a dual AMPA/NMDA receptor strategy rather than relying on transient seizure control alone.
-
PEDV Exploits IMPDH for Nucleotide Biosynthesis
2026-09-10
Zhou and colleagues show that porcine epidemic diarrhea virus (PEDV) depends on host IMPDH2-driven guanine nucleotide biosynthesis for efficient replication. By combining comparative metabolomics, IMPDH2 knockdown, and merimepodib (VX-497) treatment, the study identifies IMPDH as a promising host-directed antiviral target while highlighting cell-specific metabolic responses.
-
MRT68921 ULK1 Kinase Inhibitor Workflow
2026-09-09
Use MRT68921 to separate autophagy initiation from downstream lysosomal effects in cell-based assays. Its dual ULK1/2 activity is especially useful for validating ATG13 phosphorylation blockade, measuring LC3 flux, and testing how autophagy reshapes lipid-stress phenotypes.
-
Biotin-tyramide: Practical TSA Workflow Guide
2026-09-09
Biotin-tyramide (SKU A8011) converts localized horseradish peroxidase activity into a detectable biotin signal for immunohistochemistry and in situ hybridization workflows. It is intended for research-use TSA applications, not diagnostic testing, and requires solvent-aware preparation because it is insoluble in water.
-
DMG-PEG2000-NH2 Workflows for LNP Research
2026-09-08
DMG-PEG2000-NH2 combines a PEG2000 spacer, lipid anchor, and reactive primary amine for configurable bioconjugation in liposomes and lipid nanoparticles. This practical guide connects amide-coupling chemistry with siRNA encapsulation, surface functionalization, and assay planning inspired by optimized antimycobacterial sulfonamides.